, ,

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML – FOSTER CITY, Calif., June 9, 2023 – Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an […]

,

Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference

Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting – 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical validation study of Predictive Precision Medicine Platform FOSTER CITY, Calif., April 18, 2023 – Notable Labs, Inc. (“Notable”), a clinical stage […]

,

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

The merger agreement can be viewed from the link below: Merger Agreement  

10 Drug Discovery & Development Solution Providers of 2022 (Pharma Tech)

Published 10/18/2022 Link to: https://www.pharmatechoutlook.com/notable-labs

Notable Labs Supports the MDS Foundation’s Move for MDS Walks

Published 9/25/2022 In support of the MDS Foundation, Notable Labs took part in the “Move for MDS Walk”, a 5-cities event that brings together patients, family members and caregivers in the MDS community. Matt de Silva, Notable’s Founder and Executive Chairman, joined the event from Chicago, IL at Maggie Daley Park on September 25, 2022. […]

One company’s failed drug is this company’s ‘jewel’

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology. Meagan Parrish, Lead Editor PharmaVoice Published May 2, 2022 – Many pharma execs find that a personal experience with a patient serves as a catalyst to enter the field. For Dr. Thomas Bock, CEO of […]

Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

FOSTER CITY, CA – Dec 3, 2020 – Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, will present at the 2020 Virtual ASH Annual Meeting an update to the recently published article in Blood Advances.

Notable Labs Announces Partnership With All4Cure

FOSTER CITY, CA and SEATTLE; Oct. 28, 2020 (Business Wire) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership.

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Notable Labs Enters Into Partnership With myTomorrows

FOSTER CITY, CA – Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.